CHICAGO--(BUSINESS WIRE)--CytoCore Inc. (OTCBB:CYOE), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, announced today that the U.S. Food and Drug Administration has approved the company’s 510(k) submission to sell CytoCore’s SoftPAP™ cervical cell collector. The SoftPAP collects more comprehensive and complete cervical cell specimens for Pap testing.
